IDEAYA Biosciences, Inc. IDYA · SEC Filings

145

IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and adva...

Price32.03

Market Cap3.09 B

Float90.08 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

IDEAYA Biosciences Reports Third Quarter 2026 Financial Results and Business Updates

Nov 3, 2026

8-K

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Business Update

Aug 4, 2026

8-K

IDEAYA Biosciences, Inc. Announces Results of 2026 Annual Meeting and Board Leadership Changes

Jun 23, 2026

8-K

IDEAYA Biosciences, Inc. Announces Closing of Common Stock and Pre-Funded Warrant Offering

Jun 10, 2026

8-K

IDEAYA Biosciences Enters Clinical Collaboration with Roche for MTAP-Deleted Pancreatic Cancer

Jun 3, 2026

8-K

IDEAYA Biosciences Announces Positive Primary Results from Phase 2/3 OptimUM-02 Trial of Darovasertib Plus Crizotinib in Metastatic Uveal Melanoma

Jun 1, 2026

Prospectus

TYPE

HEADLINE

FILED AT

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Nov 3, 2026

S-3ASR

May 2026 SHELF

May 5, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 17, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 5, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 18, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 6, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 19, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 14, 2023

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 26, 2022

Ownerships

TYPE

HEADLINE

FILED AT

4

Hata Yujiro S (Reporting)

Oct 8, 2026

144

Form 144 - Report of proposed sale of securities

Oct 6, 2026

SCHEDULE 13G

BAKER BROS. ADVISORS LP (Filed by)

Aug 14, 2026

SCHEDULE 13G

VANGUARD CAPITAL MANAGEMENT LLC (Filed by)

Jul 31, 2026

4

Ruiz Briseno Andres (Reporting)

Jul 9, 2026

144

Form 144 - Report of proposed sale of securities

Jul 7, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 21, 2021

CORRESP

Form CORRESP - Correspondence

Apr 16, 2021

LETTER

Form UPLOAD - SEC-generated letter

Mar 25, 2021

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 11, 2020

CORRESP

Form CORRESP - Correspondence

Jun 9, 2020

LETTER

Form UPLOAD - SEC-generated letter

Jun 8, 2020